Augmenix Maintains Spot in Top 10% of Metro-Boston Companies; Three-Year Growth over 2,000% Ranked Company Number 207 on Inc. Magazine’s Top 500
BEDFORD, Mass.–(BUSINESS WIRE)–August 22, 2017–
Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, has again been named on Inc. magazine’s fastest-growing private companies for the second year in a row. With a three-year sales growth of 2,097 percent, the company moved from number 616 on the Top 5000 list in 2016, to number 207 on this year’s Top 500 list. The list is a coveted recognition as it showcases the leaders of America’s independent small business sector.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170822005747/en/
SpaceOAR hydrogel separates the prostate and rectum during radiation treatment (Photo: Business Wire)
A Boston-based company, Augmenix was also ranked as the sixth fastest growing company in Massachusetts and the 16th fastest growing healthcare company nationwide.
Augmenix’s exponential growth is attributed to SpaceOAR® hydrogel which reduces rectal injury in men receiving prostate cancer radiation therapy by acting as a spacer – pushing the rectum away from the prostate. This space between organs decreases the radiation dose to the rectum and other Organs at Risk (OAR). Earlier this year, Augmenix announced published data from their prospective, randomized clinical trial showing that patients treated with SpaceOAR hydrogel prior to prostate cancer radiotherapy demonstrated significant rectal (bowel), urinary, and sexual benefit through three years of follow up.
“In 2017, there will be over 160,000 new cases of prostate cancer in American men and so far, more than 15,000 patients worldwide have been successfully treated with SpaceOAR hydrogel,” said John Pedersen, CEO of Augmenix. “Radiation therapy with SpaceOAR hydrogel offers these men the unique option to have their cancer treated and preserve their post treatment Quality of Life.”
About Inc. Media:
Founded in 1979 and acquired in 2005 by Mansueto Ventures, Inc. is the only major brand dedicated exclusively to owners and managers of growing private companies, with the aim to deliver real solutions for today’s innovative company builders. Winner of the National Magazine Award for General Excellence in both 2014 and 2012. Total monthly audience reach for the brand has grown significantly from 2,000,000 in 2010 to over 15,000,000 today. For more information, visit www.inc.com.
About SpaceOAR System
Radiation therapy in the treatment of prostate cancer can cause unintended radiation injury to adjacent healthy tissue (organs at risk). This injury can lead to a range of bowel, urinary and sexual symptoms that can affect patient health and quality of life during radiotherapy, and for years afterward. In recent years, radiation oncologists have considered use of “spacing” techniques to reduce the risk of radiation injury to surrounding tissue during radiotherapy. SpaceOAR hydrogel is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR hydrogel to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR hydrogel is injected as a liquid into the space between the prostate and rectum where it pushes the structures apart and then solidifies into a soft hydrogel. The hydrogel remains stable for three months during radiation therapy then liquefies and is completely absorbed by the body. See the Instructions for Use for complete information on potential risks, warnings and precautions.
About Augmenix, Inc.
Augmenix, Inc. is a privately held U.S. company based in the Boston, Massachusetts area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. Focusing initially on protection during prostate radiation therapy, Augmenix next-generation products will address spacing and marking applications throughout the body to improve radiotherapy and interventional oncology procedure outcomes. The company’s lead product, SpaceOAR System, is FDA cleared and is currently being used in the majority of leading cancer centers in the United States. It is also CE marked, approved in Australia and licensed in Canada. SpaceOAR is a registered trademark of Augmenix, Inc. More information about Augmenix and the SpaceOAR hydrogel can be found at www.augmenix.com
EILEEN GARDNER, RN, 781-902-1625
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform
- networking features, and more